asparaginase erwinia chrysanthemi | Asparaginase Erwinia Chrysanthemi

Keyword	CPC	PCC	Volume	Score	Length of keyword
asparaginase erwinia chrysanthemi	0.41	0.2	5291	8	33
asparaginase	1.83	0.6	946	70	12
erwinia	1.66	1	6513	48	7
chrysanthemi	0.56	0.1	9067	23	12

Keyword	CPC	PCC	Volume	Score
asparaginase erwinia chrysanthemi	1.69	0.2	5018	28
asparaginase erwinia chrysanthemi recombinant	0.11	0.3	5789	38
asparaginase erwinia chrysanthemi-rywn	1.61	0.7	6214	67
asparaginase erwinia chrysanthemi rylaze	0.25	0.2	3173	11
erwinia asparaginase package insert	0.17	0.4	1466	98
asparaginase erwinia for injection	0.13	0.7	1225	52
l-asparaginase 2	1.85	0.1	8788	11

Search Results related to asparaginase erwinia chrysanthemi on Search Engine

Asparaginase Erwinia Chrysanthemi - NCI - National Cancer Institute
cancer.gov

https://www.cancer.gov/about-cancer/treatment/drugs/asparaginase-erwinia-chrysanthemi

WEBAsparaginase erwinia chrysanthemi is approved to be used with other drugs to treat: Acute lymphoblastic leukemia. It is a form of asparaginase made from the bacterium Erwinia chrysanthemi. It is used in patients who can no longer take asparaginase made from E. coli.

DA: 17 PA: 60 MOZ Rank: 89

FDA approves asparaginase erwinia chrysanthemi (recombinant) …
fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asparaginase-erwinia-chrysanthemi-recombinant-leukemia-and-lymphoma

WEBOn June 30, 2021, the Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as a component of a multi-agent...

DA: 25 PA: 5 MOZ Rank: 99

FDA Approves Rylaze for Childhood ALL - NCI - National Cancer Institute
cancer.gov

https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-rylaze-asparaginase-childhood-leukemia

WEBJul 29, 2021 · On June 30, FDA approved a new form of asparaginase, erwinia chrysanthemi (recombinant)-rywn (Rylaze), which was developed to address the ongoing shortages of Erwinia asparaginase. Rylaze was approved as part of a treatment regimen for children and adults with ALL or lymphoblastic lymphoma (LBL), a rare but aggressive …

DA: 70 PA: 59 MOZ Rank: 64

Asparaginase Erwinia Chrysanthemi (Injection Route) Description …
mayoclinic.org

https://www.mayoclinic.org/drugs-supplements/asparaginase-erwinia-chrysanthemi-injection-route/description/drg-20075340

WEBFeb 1, 2024 · Asparaginase Erwinia chrysanthemi is used together with other cancer medicines to treat a certain type of blood cancer called acute lymphoblastic leukemia (ALL). This medicine is used in patients who have had an …

DA: 50 PA: 73 MOZ Rank: 72

Asparaginase - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Asparaginase

WEBIn June 2021, the FDA approved asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in people aged one month or older who have developed hypersensitivity to E. coli-derived asparaginase.

DA: 18 PA: 30 MOZ Rank: 55

Asparaginase Erwinia chrysanthemi Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/asparaginase-erwinia-chrysanthemi.html

WEBDec 14, 2022 · Asparaginase Erwinia chrysanthemi is a cancer medicine. Erwinase is used to treat acute lymphoblastic leukemia in adults and children at least 4 months old who have become allergic to other forms of asparaginase such as Elspar, Oncaspar or Rylaze.

DA: 2 PA: 7 MOZ Rank: 40

FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi
fda.gov

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-dosing-regimen-asparaginase-erwinia-chrysanthemi-recombinant

WEBOn November 18, 2022, the Food and Drug Administration approved a new Monday-Wednesday-Friday dosing regimen for asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze, Jazz...

DA: 54 PA: 65 MOZ Rank: 51

Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn - NCI
cancer.gov

https://www.cancer.gov/about-cancer/treatment/drugs/asparaginase-erwinia-chrysanthemi-recombinant

WEBAsparaginase erwinia chrysanthemi (recombinant)-rywn is approved to treat adults and children aged 1 month and older with: Acute lymphoblastic leukemia. Lymphoblastic lymphoma. Asparaginase erwinia chrysanthemi (recombinant)-rywn is used in patients who can no longer take asparaginase made from E. coli.

DA: 50 PA: 80 MOZ Rank: 81

Asparaginase Erwinia chrysanthemi - DrugBank Online
drugbank.com

https://go.drugbank.com/drugs/DB08886

WEBMay 27, 2013 · Asparaginase Erwinia chrysanthemi is an enzyme that exerts cytotoxic effects on leukemic cells by depleting the source of an amino acid asparagine, which plays a role in the proliferation, protein metabolism, and survival of …

DA: 100 PA: 23 MOZ Rank: 68

Asparaginase erwinia chrysanthemi | Leukemia and Lymphoma …
lls.org

https://www.lls.org/drug/asparaginase-erwinia-chrysanthemi

WEBAsparaginase Erwinia chrysanthemi is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. Side effects needing medical attention.

DA: 84 PA: 76 MOZ Rank: 34